Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - tetanus protein, quantity: 22 microgram; haemophilus type b polysaccharide, quantity: 12 microgram; pertussis toxoid, quantity: 25 microgram; diphtheria toxoid, quantity: 20 iu; poliovirus, quantity: 8 dagu; poliovirus, quantity: 40 dagu; tetanus toxoid, quantity: 40 iu; pertussis filamentous haemagglutinin, quantity: 25 microgram; poliovirus, quantity: 32 dagu; hepatitis b surface antigen, quantity: 10 microgram - injection, suspension - excipient ingredients: sucrose; monobasic potassium phosphate; dibasic sodium phosphate heptahydrate; water for injections; aluminium hydroxide hydrate; trometamol; tyrosine; arginine hydrochloride; histidine; isoleucine; leucine; lysine hydrochloride; phenylalanine; threonine; tryptophan; valine; cystine; methionine - hexaxim is indicated for vaccination of infants from six weeks of age against diphtheria, tetanus, pertussis, hepatitis b, poliomyelitis and invasive infections caused by haemophilus influenzae type b. use of this vaccine should be in accordance with the national recommendation as per the current immunisation handbook.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - meningococcal oligosaccharide group y, quantity: 5 microgram; meningococcal oligosaccharide group c, quantity: 5 microgram; diphtheria crm197 protein, quantity: 16 microgram; meningococcal oligosaccharide group w135, quantity: 5 microgram - injection, solution - excipient ingredients: sodium chloride; water for injections; monobasic sodium phosphate monohydrate; dibasic sodium phosphate dihydrate - menveo is indicated for active immunisation of infants and children (from 2 months of age), adolescents and adults to prevent invasive disease caused by neisseria meningitidis serogroups a, c, w-135 and y. the use of this vaccine should be in accordance with official recommendations.

Bangladexx - Ingliż - DGDA (Directorate General of Drug Administration)

incepta pharmaceuticals ltd., vaccine division - bordetella pertussis + diphtheria toxoid + haemophilus influenzae type b conjugated + hepatitis b surface antigen + tetanus toxoid - vaccine - 4 iu + 30 iu + 10 mcg + 10 mcg + 60 iu/.5 ml

Iżrael - Ingliż - Ministry of Health

sanofi israel ltd - conjugated to tetanus protein; diphtheria toxoid; filamentous haemagglutinin (fha); haemophilus influenzae type b polysaccharide; pertussis toxoid (pt); polio type i (mohoney); polio type ii ( m.e.f.1); polio type iii (saukett); tetanus toxoid - powder and suspension for suspension for injection - polio type iii (saukett) 32 du / 0.5 ml; polio type ii ( m.e.f.1) 8 du / 0.5 ml; polio type i (mohoney) 40 du / 0.5 ml; filamentous haemagglutinin (fha) 25 mcg / 0.5 ml; pertussis toxoid (pt) 25 mcg / 0.5 ml; tetanus toxoid 40 iu / 0.5 ml; diphtheria toxoid 30 iu / 0.5 ml; haemophilus influenzae type b polysaccharide 10 mcg / 0.5 ml; conjugated to tetanus protein 18-30 mcg / 0.5 ml - diphtheria-hemophilus influenzae b-pertussis-poliomyelitis-tetanus - active immunisation against diphtheria, tetanus, pertussis, poliomyelitis and invasive infections caused by haemophilus influenzae type b (meningitis, septicaemia, cellulitis, arthritis, epiglottitis, …)• for primary vaccination in infants.• for booster in children who have previously received a primary vaccination with this vaccine or a diphtheria-tetanus-whole-cell or acellular pertussis poliomyelitis vaccine, whether mixed or not with freeze-dried conjugate haemophilus influenzae type b vaccine.

Filippini - Ingliż - FDA (Food And Drug Administration)

n/a; importer: sanofi pasteur, inc.; distributor: sanofi pasteur, inc. - diphtheria, tetanus, pertussis (whole cell), hepatitis b (idna) and haemophilus influenzae type b conjugate vaccine (adsorbed) - suspension for injection (im) - formulation: each dose (0.5 ml) contains: diphtheria toxoid->30iu tetanus toxoid->60iu bordetella pertussis (whole cell)-> 4 iu hepatitis b (r-dna) surface antigen-10ug purified capsular polysaccharide of hib conjugated to 20-40 mcg tetanus toxoid (carrier protein)-10ug

Unjoni Ewropea - Ingliż - EMA (European Medicines Agency)

sanofi pasteur msd, snc - polyribosylribitol phosphate from haemophilus influenzae type b as prp-ompc, outer membrane protein complex of neisseria meningitidis (outer membrane protein complex of the b11 strain of neisseria meningitidis subgroup b), adsorbed hepatitis b surface antigen produced in recombinant yeast cells (saccharomyces cerevisiae) - hepatitis b; meningitis, haemophilus; immunization - vaccines - procomvax is indicated for vaccination against invasive disease caused by haemophilus influenzae type b and against infection caused by all known subtypes of hepatitis b virus in infants 6 weeks to 15 months of age.,

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - haemophilus influenza type b polyribose ribitol phosphate,meningococcal polysaccharide group c,tetanus toxoid -

Filippini - Ingliż - FDA (Food And Drug Administration)

n/a; importer: ip biotech, inc.; distributor: ip biotech, inc. - diphtheria, tetanus, pertussis (whole cell), hepatitis b (rdna) and haemophilus influenzae type b conjugate vaccine (adsorbed) - solution for injection (i.m) - each dose (0.5 ml) contains: diphtheria toxoid ................... 25 lf ( > 30 iu) tetanus toxoid ...................... 5.5 lf (> 60 iu) b. pertussis (whole cell) ........... 16 iou ( >4 iu) hepatitis b (rdna) ................ 12.5 ug purified capsular polysaccharide (prp) of hib covalently linked to 20 to 36.7 ug of tetanus toxoid .... ............... 11 ug alt+t (as alpo4) ........ ............. <1.25 mg thiomersal ............ ........... 0.01% w/v

Filippini - Ingliż - FDA (Food And Drug Administration)

n/a; importer: ip biotech, inc.; distributor: ip biotech, inc. - diphtheria, tetanus, pertussis (whole cell), hepatitis b (rdna) and haemophilus influenzae type b conjugate vaccine (adsorbed) - suspension for injection (im) - each dose (0.5 ml) contains: diphtheria toxoid 25 lf 30 iu) tetanus toxoid....................... 5.5 lf 60 iu) b. pertussis (whole cell ............ 16 iou ( 4 iu) hepatitis b (rdna)................12.5 ug purified capsular polysaccharide (prp) of hib covalently linked to 20 to 36.7 ug of tetanus toxoid ..................11 ug alt++ (as alpo4)..................... 51.25 mg thiomersal .......... 0.01% w/v

Filippini - Ingliż - FDA (Food And Drug Administration)

n/a; importer: sanofi pasteur, inc.; distributor: sanofi pasteur, inc. - diphtheria, tetanus, pertussis (whole cell), hepatitis b (idna) and haemophilus influenzae type b conjugate vaccine (adsorbed) - suspension for injection (im) - formulation: each dose (0.5 ml) contains: diphtheria toxoid-> 30 iu tetanus toxoid- > 60 iu bordetella pertussis (whole cell)-> 4u hepatitis b (r-dna) surface antigen-10 ug purified capsular polysaccharide of hib conjugated to 20-40 mcg tetanus toxoid (carrier protein)-10 ug